In vitro activity of DNF-3 against drug-resistant Mycobacterium tuberculosis
- Authors
- Islam, Md Imtiazul; Han, Choi Moon; Seo, Hoonhee; Kim, Sukyung; Al Mahmud, Hafij; Nam, Kung-Woo; Lee, Byung-Eui; Sadu, Venkata S.; Lee, Kee-In; Song, Ho-Yeon
- Issue Date
- Jul-2019
- Publisher
- Elsevier BV
- Keywords
- DNF-3; Multidrug-resistant; Extensively drug-resistant; MDR/XDR-TB; Mycobacterium tuberculosis; NTM
- Citation
- International Journal of Antimicrobial Agents, v.54, no.1, pp 69 - 74
- Pages
- 6
- Journal Title
- International Journal of Antimicrobial Agents
- Volume
- 54
- Number
- 1
- Start Page
- 69
- End Page
- 74
- URI
- https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/4452
- DOI
- 10.1016/j.ijantimicag.2019.02.013
- ISSN
- 0924-8579
1872-7913
- Abstract
- Due to the emergence of multidrug-resistant and extensively drug-resistant (XDR) strains of Mycobacterium tuberculosis, new antituberculosis drugs are urgently required to improve the efficacy of current tuberculosis (TB) treatment. To achieve this goal, ca. 1000 chemical compounds were screened for potential antimycobacterial activity, among which methyl 5-(2-diethylaminoethoxy)-7,12-dioxo-7,12 dihydrodinaphtho[1,2-b;2',3'-d]furan-6-carboxylate (DNF-3) showed strong activity against all of the tested drug-susceptible and -resistant M. tuberculosis strains, with 50% minimum inhibitory concentrations (MIC50 values) of 0.02-0.39 mu g/mL both in culture broth and within murine RAW 264.7 macrophage cells. When DNF-3 was used in combination with rifampicin or streptomycin, it exhibited direct synergy against XDR-TB and an additive effect against M. tuberculosis H37Rv. DNF-3 displayed a long post-antibiotic effect (PAE) that was comparable with rifampicin but was superior to isoniazid, streptomycin and ethambutol. Importantly, DNF-3 showed no cytotoxicity to any cell line tested, with a selectivity index (SI) of >32. DNF-3 was also active against 27 nontuberculous mycobacteria (NTM) strains, Staphylococcus spp. and Streptococcus spp. Taken together, these results indicate that DNF-3 is a promising new candidate drug for treating TB. Further studies are warranted to establish the in vivo effect and therapeutic potential of DNF-3. (C) 2019 Published by Elsevier B.V.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Microbiology > 1. Journal Articles
- College of Natural Sciences > Department of Biology > 1. Journal Articles
- College of Medicine > Department of Internal Medicine > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/4452)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.